BIOMAT Database Logo BIOMAT Database Logo

[Early results of ethambutol treatment in patients with cavernous pulmonary tuberculosis and resistance to many antitubercular agents]. 1971

M Kamińska, and L Czajka-Kropaczek, and A Ciechanowska

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D004977 Ethambutol An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863) Dexambutol,EMB-Fatol,EMB-Hefa,Etambutol Llorente,Ethambutol Hydrochloride,Etibi,Miambutol,Myambutol,EMB Fatol,EMB Hefa,Hydrochloride, Ethambutol,Llorente, Etambutol
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

M Kamińska, and L Czajka-Kropaczek, and A Ciechanowska
[Results of intermittent treatment with antitubercular agents in cavernous pulmonary tuberculosis in adults].
January 1976, Revista de igiena, bacteriologie, virusologie, parazitologie, epidemiologie, pneumoftiziologie. Pneumoftiziologia,
M Kamińska, and L Czajka-Kropaczek, and A Ciechanowska
[Rifampicin combined with ethambutol and other antitubercular agents in the treatment of patients with chronic pulmonary tuberculosis. Early results. II. Analysis of causes of treatment interruption].
February 1976, Pneumonologia polska,
M Kamińska, and L Czajka-Kropaczek, and A Ciechanowska
[Early results of Ethambutol treatment of 28 patients with pulmonary tuberculosis].
February 1971, Polski tygodnik lekarski (Warsaw, Poland : 1960),
M Kamińska, and L Czajka-Kropaczek, and A Ciechanowska
[Ethambutol in the treatment of chronic pulmonary tuberculosis in patients excreting organisms resistant to several antitubercular agents].
July 1971, Gruzlica i choroby pluc; tuberculosis et pneumonologia,
M Kamińska, and L Czajka-Kropaczek, and A Ciechanowska
[Rifampicin combined with ethambutol and other antitubercular drugs in the treatment of patients with pulmonary tuberculosis. Early results. I. Bacteriological evaluation].
January 1976, Pneumonologia polska,
M Kamińska, and L Czajka-Kropaczek, and A Ciechanowska
[Early results of rifampicin treatment combined with other antitubercular agents in patients with recent and chronic pulmonary tuberculosis].
February 1979, Pneumonologia polska,
M Kamińska, and L Czajka-Kropaczek, and A Ciechanowska
[THE RESULTS OF ORIGINAL TREATMENT OF FIBROUS-CAVERNOUS PULMONARY TUBERCULOSIS WITH ANTITUBERCULAR CHEMOTHERAPY].
November 1964, Gruzlica (Warsaw, Poland : 1926),
M Kamińska, and L Czajka-Kropaczek, and A Ciechanowska
[Ethambutol in the treatment of chronic cavernous tuberculosis resistant to many antituberculous drugs].
March 1968, Gruzlica i choroby pluc; tuberculosis et pneumonologia,
M Kamińska, and L Czajka-Kropaczek, and A Ciechanowska
[Results of the treatment in patients with pulmonary tuberculosis excreting bacilli in primary resistance to antitubercular drugs].
October 1965, Gruzlica i choroby pluc; tuberculosis et pneumonologia,
M Kamińska, and L Czajka-Kropaczek, and A Ciechanowska
[Remote results of pulmonary tuberculosis therapy with antitubercular agents and corticotropin].
January 1970, Problemy tuberkuleza,
Copied contents to your clipboard!